Table 1.

Patient demographics and baseline characteristics

	AZD4547 dose
	Part A					Part B
	40 mg bid	80 mg bid	120 mg bid	160 mg qd	Total Part A	80 mg bid
	(N = 3)	(N = 6)	(N = 6)	(N = 15)	(N = 30)	(N = 4)
Sex, n (%)
Female	1 (33.3)	4 (66.7)	2 (66.7)	7 (46.7)	14 (46.7)	1 (25.0)
Male	2 (66.7)	2 (33.3)	4 (33.3)	8 (53.3)	16 (53.5)	3 (75.0)
Median age, years	49	63.5	61.5	66.0	63.5	71.5
(range)	(41–73)	(30–76)	(47–76)	(51–78)	(30–78)	(64–76)
WHO performance status, n (%)
0	3 (100)	5 (83.3)	3 (50.0)	7 (46.7)	18 (60.0)	2 (50.0)
1	0 (0)	1 (16.7)	3 (50.0)	8 (53.3)	12 (40.0)	2 (50.0)
Local/metastatic sites, n (%)
Local only	0 (0)	0 (0)	1 (16.7)	1 (6.7)	2 (6.7)	0
Local/metastatic	3 (100)	6 (100)	5 (83.3)	14 (93.3)	28 (93.3)	4 (100)
Common primary tumour types, n (%)
Bile duct	0 (0)	0 (0)	0 (0)	1 (6.7)	1 (3.3)	0 (0)
Bladder	0 (0)	0 (0)	0 (0)	1 (6.7)	1 (3.3)	0 (0)
Breast	0 (0)	4 (66.7)	0 (0)	1 (6.7)	5 (16.7)	1 (25.0)
Caecum	1 (33.3)	0 (0)	0 (0)	0 (0)	1 (3.3)	0 (0)
Colon	1 (33.3)	1 (16.7)	0 (0)	0 (0)	2 (6.7)	0 (0)
Colorectal	0 (0)	0 (0)	0 (0)	1 (6.7)	1 (3.3)	0 (0)
Lung	0 (0)	1 (16.7)	3 (50.0)	6 (40.0)	10 (33.3)	1 (25.0)
Oesophagus	0 (0)	0 (0)	0 (0)	1 (6.7)	1 (3.3)	0 (0)
Pancreas	0 (0)	0 (0)	1 (16.7)	0 (0)	1 (3.3)	0 (0)
Rectal	0 (0)	0 (0)	0 (0)	1 (6.7)	1 (3.3)	0 (0)
Stomach	0 (0)	0 (0)	1 (16.7)	3 (20.0)	4 (13.3)	2 (50.0)
Thymus	1 (33.3)	0 (0)	0 (0)	0 (0)	1 (3.3)	0 (0)
Urachus	0 (0)	0 (0)	1 (16.7)	0 (0)	1 (3.3)	0 (0)
Prior therapy, n (%)
Chemotherapy	2 (66.7)	6 (100)	6 (100)	15 (100)	29 (96.7)	4 (100)
Other systemic anticancer therapy	2 (66.7)	2 (33.3)	1 (16.7)	6 (40.0)	11 (36.7)	1 (25.0)
Radiotherapy	3 (100)	6 (100)	6 (100)	15 (100)	30 (100)	4 (100)
Hormonal/immunotherapy	0 (0)	1 (16.7)	0 (0)	2 (13.3)	3 (33.3)	0 (0)